Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Active Pharmaceutical Ingredients. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Solve water-sensitive impurity issues in Gefitinib intermediate synthesis. Our method achieves >99% yield and >97% purity using solid carbonates, eliminating costly post-treatment steps. Ideal for scale-up.
Solve meloxicam production challenges with DMSO-based synthesis: 92% yield, 99.5% purity, and reduced toxic solvent use. Scale efficiently with CDMO expertise.
Solve ibrutinib impurity issues with mixed base method: 90% yield, no flocs, 0.1% single impurity. Scale to 100MT/yr with NINGBO INNO PHARMCHEM.
Solve high cost & low yield in ezetimibe production. New chiral catalyst method cuts steps, boosts 86% yield & 99.8% purity. Scale with CDMO expertise.
Solve high-cost, low-yield issues in Ribociclib production. Our CDMO leverages patent-validated metal-free routes for 99.8% purity, 5-step synthesis, and scalable manufacturing.
Solve silodosin production challenges with 55.6% yield and 99.1% ee. Avoid difficult byproduct separation and reduce costs. CDMO expertise for scalable API manufacturing.
Solve supply chain risks in indolo[2,1a]isoquinoline production with CO substitute technology. 92% yield, 24h reaction, and broad functional group tolerance for API manufacturing.
Solve Sacubitril synthesis challenges with new chiral control strategy. Reduce production costs, improve yield, and ensure supply chain stability for heart failure treatments.
Struggling with low yields and impurities in 5-(3,3-dimethylguanidino)-2-oxopentanoic acid synthesis? Discover emerging stable processes and find reliable suppliers for consistent API production.